Skip to main content
SynAct Pharma logo

SynAct Pharma — Investor Relations & Filings

Ticker · SYNACT ISIN · SE0008241491 LEI · 549300RRYIEFEQ72N546 ST Manufacturing
Open in API
Filings indexed 223 across all filing types
Latest filing 2023-10-17 Major Shareholding Noti…
Country SE Sweden
Listing ST SYNACT

About SynAct Pharma

https://synactpharma.com/en/

SynAct Pharma is a clinical-stage biotechnology company developing innovative medicines designed to resolve inflammation rather than solely inhibit it. The company's approach focuses on resolution therapy by leveraging melanocortin biology to restore immune balance. Its lead candidate, Resomelagon (AP1189), is a once-daily oral therapy that selectively activates melanocortin receptors on key immune cells. SynAct Pharma's development programs target a broad range of inflammatory conditions, including early intervention in chronic diseases to limit progression and the modulation of hyperinflammatory stages in acute viral diseases to reduce the risk of severe organ dysfunction.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2023
Major Shareholding Notification Classification · 98% confidence The document details a change in shareholding percentage for 'Colombus International Holdings, Inc.' in 'SynAct Pharma AB', specifically reporting the 'Before the transaction' and 'After the transaction' share quantities and resulting voting rights percentages (10.5423%). This type of filing, which reports changes in significant ownership levels crossing specific thresholds (implied by the structure and the mention of a 10% limit), directly corresponds to the definition of a Major Shareholding Notification. The filing code for Major Shareholding Notification is MRQ.
2023-10-17 English
SynAct Pharma AB publishes prospectus in connection with admission to trading of new shares on Nasdaq Stockholm
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that SynAct Pharma AB has published a simplified prospectus regarding the admission to trading of new shares on Nasdaq Stockholm, following a directed issue. The text explicitly mentions the approval and registration of the 'Prospectus' by the Swedish Financial Supervisory Authority and provides links to the document. Since this is an announcement about the publication of a formal document (a prospectus related to a capital change/share issue) rather than the comprehensive financial report itself (like a 10-K or IR), and it is a formal regulatory announcement, it fits best under the category for announcements related to capital/financing activities or a general regulatory filing. Given the context of a prospectus for new share admission, 'Capital/Financing Update' (CAP) is highly relevant, but the document itself is structured as a formal announcement of publication. However, the core event being announced is the capital change/share issuance related to the prospectus. Since the prospectus itself is the key document being released, and it relates to the issuance of new shares, 'CAP' (Capital/Financing Update) is a strong candidate. Alternatively, because it is a formal announcement of a regulatory document publication, 'RPA' (Report Publication Announcement) or 'RNS' (Regulatory Filings) could apply. Given the specific nature of the capital event (issuance of new shares leading to a prospectus), CAP is more specific than RPA or RNS. I will classify it as CAP because the subject matter is financing/capital structure change, even though it is presented as a publication announcement.
2023-10-12 English
SynAct Pharma AB offentliggör prospekt med anledning av upptagande till handel av nyemitterade aktier på Nasdaq Stockholm
Report Publication Announcement Classification · 99% confidence The document is a press release from SynAct Pharma AB announcing that the Board has prepared a simplified prospectus ('Prospektet') following a directed share issue, and this prospectus has been approved and registered by the Swedish Financial Supervisory Authority (Finansinspektionen) in connection with the listing of the new shares on Nasdaq Stockholm. The core subject is the creation and approval of a prospectus related to a capital action (share issuance/listing). This directly relates to financing activities and capital structure changes. While a prospectus is often associated with a public offering, the context here is the listing following a directed issue, which falls under 'Capital/Financing Update' (CAP). It is not the full Annual Report (10-K), an Earnings Release (ER), or a general regulatory filing (RNS), as it describes a specific capital event and the associated required documentation (the prospectus). Since the document is an announcement about the prospectus being ready and approved, it strongly aligns with the definition of Capital/Financing Update (CAP).
2023-10-12 Swedish
SynAct Pharma AB genomför en riktad emission av aktier och teckningsoptioner och tillförs härigenom en initial bruttolikvid om 60,5 MSEK
Capital/Financing Update Classification · 98% confidence The document is a press release from SynAct Pharma AB announcing a directed share and warrant issue (a financing activity) that raises 60.5 MSEK initially. Key phrases include "riktad emission av aktier och teckningsoptioner" (directed issue of shares and warrants), the amount raised ("bruttolikvid om 60,5 MSEK"), and the purpose (funding clinical studies and business development). This clearly falls under the category of updates on company fundraising or capital structure changes. The document also mentions that a prospectus is expected to be approved and published later, which suggests this announcement itself is the primary financing event notification, not the subsequent report (RPA) or the final prospectus. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2023-10-11 Swedish
SynAct Pharma AB carries out a directed issue of shares and warrants raising initial gross proceeds of SEK 60.5 million
Capital/Financing Update Classification · 98% confidence The document is a press release announcing a 'directed issue of shares and warrants' which raises capital (SEK 60.5 million initially). This action directly relates to the company's capital structure and fundraising activities. The key terms are 'directed issue,' 'shares,' 'warrants,' and 'raising proceeds.' This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). Although it mentions a prospectus will be prepared, the core content is the financing transaction itself, not just the announcement of the report (RPA) or a general regulatory filing (RNS). The document length is substantial (over 17k characters), indicating it is the primary announcement, not just a brief notice.
2023-10-11 English
SynAct Pharma announces additional data from the EXPAND P2b clinical trial and identifies population with responsiveness to resomelagon
Earnings Release Classification · 95% confidence The document is a press release announcing additional clinical trial data (EXPAND P2b) for a drug (resomelagon) and scheduling an investor webcast. It details efficacy results (ACR20, CRP levels) and mentions future data releases (MRI sub-study, RESOLVE Part 2a). This content is characteristic of an initial announcement of periodic financial/operational results, focusing on key operational highlights rather than a comprehensive report (like 10-K or IR). The presence of an investor webcast announcement strongly suggests this is an Earnings Release (ER) or a similar operational update. Since it is not a full transcript (CT) or a comprehensive quarterly report (IR), and it focuses on results, ER is the most appropriate classification. The document length (8808 chars) is substantial enough to be the release itself, not just a brief RPA. FY 2023
2023-09-12 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.